ORIGINAL PAPER
Antibiotic therapy of choice for community-acquired pneumonia in Malaysian Hajj pilgrims: the pattern and associated factors
1
Faculty of Medicine, University Sultan Zainal Abidin, Terengganu, Malaysia
2
Unit of Microbiology, Faculty of Medicine, University Sultan Zainal Abidin, Terengganu, Malaysia
3
Unit of Pharmacology, Faculty of Medicine and Defence Health, National Defence University of Malaysia, Kuala Lumpur, Malaysia
4
USM-KLE International Medical Programme, Belgaum, Karnataka, India
5
University Sultan Zainal Abidin (UniSZA), Terengganu Darul Iman, Malaysia
6
Unit of the Community Medicine, Faculty of Medicine, University Sultan Zainal Abidin, Terengganu, Malaysia
7
Department of Respiratory Medicine, Institute of Respiratory Medicine, Hospital Kuala Lumpur, Kuala Lumpur, Malaysia
Submission date: 2016-10-22
Final revision date: 2017-05-17
Acceptance date: 2017-06-30
Publication date: 2017-09-30
Medical Studies 2017;33(3):199-207
KEYWORDS
TOPICS
ABSTRACT
Introduction: Pneumonia is a potentially life-threatening illness that poses global health teething troubles particularly among elderly population and performing Hajj. Empirical antibiotic treatment has been recommended for all suspected community-acquired pneumonia (CAP) patients as initial treatment on admission.
Aim of the research: To describe the antibiotic therapy of CAP and determine the associated factors related to the treatment options among Malaysian Hajj pilgrims.
Material and methods: This was a cross-sectional study involving 91 patients who were admitted to Tabung Haji Hospital, Makkah in 2012, with the clinical diagnosis of pneumonia during Hajj season. The antibiotic treatment for the patients as well as demographic factors and co-morbidity, which potentially influence the treatment options, were studied.
Results: The mean age of the hajj pilgrims was 71.4 ±8.7 years. The most frequently prescribed antibiotic was levofloxacin (44.0%), followed by azithromycin (40.7%), cefuroxime (23.1%), ampicillin + sulbactam (16.5%), and amoxicillin + clavulanate (15.4%). The age of patients was significantly associated with levofloxacin, azithromycin, and meropenem (p = 0.032, 0.028, and 0.026, respectively). Patients with diabetes were statistically significantly highly prescribed with cefuroxime (p = 0.036).
Conclusions: Levofloxacin and azithromycin were classified as the most common antibiotic treatment given to Malaysian Hajj pilgrim with CAP and their choice was associated with older age of patients. Otherwise, cefuroxime was the prescription of choice in diabetics.
Aim of the research: To describe the antibiotic therapy of CAP and determine the associated factors related to the treatment options among Malaysian Hajj pilgrims.
Material and methods: This was a cross-sectional study involving 91 patients who were admitted to Tabung Haji Hospital, Makkah in 2012, with the clinical diagnosis of pneumonia during Hajj season. The antibiotic treatment for the patients as well as demographic factors and co-morbidity, which potentially influence the treatment options, were studied.
Results: The mean age of the hajj pilgrims was 71.4 ±8.7 years. The most frequently prescribed antibiotic was levofloxacin (44.0%), followed by azithromycin (40.7%), cefuroxime (23.1%), ampicillin + sulbactam (16.5%), and amoxicillin + clavulanate (15.4%). The age of patients was significantly associated with levofloxacin, azithromycin, and meropenem (p = 0.032, 0.028, and 0.026, respectively). Patients with diabetes were statistically significantly highly prescribed with cefuroxime (p = 0.036).
Conclusions: Levofloxacin and azithromycin were classified as the most common antibiotic treatment given to Malaysian Hajj pilgrim with CAP and their choice was associated with older age of patients. Otherwise, cefuroxime was the prescription of choice in diabetics.
REFERENCES (54)
1.
Ebrahim SH, Memish ZA, Uyeki TM, Khoja TAM, Marano N, McNabb SJN. Pandemic H1N1 and the 2009 Hajj. Science 2009; 326: 938-40.
2.
Dzaraly ND, Rahman NIA, Haque M, Simbak NB, Wahab MSA, Aziz AA, Abdulllah MS, Mohamad I, Muttalif ARA, Ismail S, Abdullah S. The characteristics of hospitalized pneumonia patients among Malaysian Hajj Pilgrims. J Young Pharm 2016; 8: 284-90.
3.
Dzaraly ND, Rahman NI, Simbak NB, Wahab SA, Osman O, Ismail S, Haque M. Patterns of communicable and noncommunicable diseases in Pilgrims during Hajj. Res J Pharm Tech 2014; 7: 1052-9.
4.
Al-Ghamdi SM, Akbar HO, Qari YA, Fathaldin OA, Al-Rashed RS. Pattern of admission to hospitals during Muslim pilgrimage (Hajj). Saudi Med J 2003; 24: 1073-6.
5.
Asghar AH, Ashshi AM, Azhar EI, Bukhari SZ, Zafar TA, Momenah AM. Profile of bacterial pneumonia during Hajj. Indian J Med Res 2011; 133: 510-3.
6.
Mandell LA, Wunderink RG, Anzueto A, Bartlett JG, Campbell GD, Dean NC, Dowell SF, File TM Jr, Musher DM, Niederman MS, Torres A, Whitney CG. Infectious Diseases Society of America; American Thoracic Society. Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. Clin Infect Dis 2007; 44: S27-72.
8.
Feldman C, Brink AJ, Richards GA, Maartens G, Bateman ED. Management of community acquired pneumonia in adults. South Afr Med J 2008; 23: 31-42.
9.
Lim WS, Baudouin SV, George RC, Hill AT, Jamieson C, Le Juene I, Macfarlane JT, Read RC, Roberts HJ, Levy ML, Wani M, Woodhead MA. Pneumonia Guidelines Committee of the BTS Standards of Care Committee. BTS guidelines for the management of com- munity acquired pneumonia in adults: update 2009. Thorax 2009; 64: iii1-55.
10.
Patterson CM, Loebinger MR. Community acquired pneumonia: assessment and treatment. Clin Med (Lond) 2012; 12: 283-6.
11.
Bartlett JG, Breiman RF, Mandell LA, File TM Jr. Community-acquired pneumonia in adults: guideline for management. Infectious Diseases Society of America. Clin Infect Dis 1998; 26: 811-38.
12.
British Thoracic Society. Guidelines for the management of community-acquired pneumonia in adults admitted to hospital. Brit J Hosp Med 1993; 49: 346-50.
13.
Mandell LA, Niederman MS. The Canadian community-acquired pneumonia consensus group. Antimicrobial treatment of community acquired pneumonia in adults: a conference report. Can J Infect Dis 1993; 4: 25-8.
14.
Niederman MS, Bass JB Jr, Campell GD, Fein AM, Grossman RF, Mandell LA, Marrie TJ, Sarosi GA, Torres A, Yu VL. Guidelines for the initial management of adults with community-acquired pneumonia: diagnosis, assessment of severity, and initial antimicrobial therapy. American Thoracic Society. Medical Section of the American Lung Association. Am Rev Respir 1993; 148: 1418-26.
15.
Mandell LA, Marrie TJ, Grossman RF, Chow AW, Hyland RH; Canadian Community-acquired Pneumonia Working Group. Canadian guidelines for initial management of community-acquired pneumonia: an evidencebased update by the Canadian Infectious Disease Society and Canadian Thoracic Society. Clin Infect Dis 2000; 31: 383-421.
16.
Haque M, Rahman NIA, Zulkifli Z, Ismail S. Antibiotic prescribing and resistance: knowledge level of medical students of clinical years of University Sultan Zainal Abidin, Malaysia. Ther Clin Risk Manag 2016; 12: 413-26.
17.
Hoque R, Mostafa A, Haque M. Intern doctors’ views on the current and future antibiotic resistance situation of Chattagram Maa O Shishu Hospital Medical College, Bangladesh. Ther Clin Risk Manag 2015; 11: 1177-85.
18.
Salam A, Haque M, Islam MZ, Rahman NIA, Helali AM, Muda TFMBT, Yousuf R, Yesmin F, Rahman Z, Alattraqchi AG. Addressing rational prescribers through the pharmacology and therapeutics course work of MBBS syllabus in Bangladesh. Int Res J Pharm 2013; 4: 60-3.
19.
Islam MZ, Rahman MF, Mossaddek ASM, Rozario RJ, Iftekhar AFMH, Akhter S, Jahan I, Helali AM, Dali WPEW, Ismail S, Rahman NIA, Haque M. Bangladeshi interns’ knowledge of pharmacology and therapeutics for prescribing. J App Pharm Sci 2014; 4: 043-51.
20.
Hoque R, Mostafa A, Haque M. Insight of medical students of clinical years to antimicrobials prescribing and resistance in a Private Medical School Chattagram Maa O Shishu Hospital Medical College, Chittagong, Bangladesh. J Young Pharm 2016; 8: 447-55.
21.
Llor C, Bjerrum L. Antimicrobial resistance: risk associated with antibiotic overuse and initiatives to reduce the problem. Ther Adv Drug Saf 2014; 5: 229-41.
22.
Levy SB. Factors impacting on the problem of antibiotic resistance. J Antimicrob Chemother 2002; 49: 25-30.
23.
World Health Organization. Antimicrobial Resistance Global Report on Surveillance. WHO Press, World Health Organization, 20 Avenue Appia, 1211 Geneva 27, Switzerland 2014. Available at: http://apps.who.int/iris/bitst... 1/9789241564748_eng.pdf [Accessed on 6-May-2016].
24.
US Department of Health and Human Services. Centers for Disease Control Prevention. Antibiotic Resistance Threats in The United States, 2013. Available at: http://www.cdc.gov/drugresista... [Accessed on 6-May-2016].
25.
Ventola CL. The antibiotic resistance crisis. Part 1: causes and threats. Pharm Ther 2015; 40: 277-83.
26.
O’Neill J. Review on antimicrobial resistance: antimicrobial resistance: tackling a crisis for the health and wealth of nations. London: Wellcome Trust. 2014. Available at: http://amr-review.org/sites/de... [Accessed on 6-May-2016].
27.
Smith RD, Coast J. Antimicrobial resistance: a global response. Bull World Health Organ 2002; 80: 126-33.
28.
Bush K, Courvalin P, Dantas G, Davies J, Eisenstein B, Huovinen P, Jacoby GA, Kishony R, Kreiswirth BN, Kutter E, Lerner SA, Levy S, Lewis K, Lomovskaya O, Miller JH, Mobashery S, Piddock LJ, Projan S, Thomas CM, Tomasz A, Tulkens PM, Walsh TR, Watson JD, Witkowski J, Witte W, Wright G, Yeh P, Zgurskaya HI. Tackling antibiotic resistance. Nat Rev Microbiol 2011; 9: 894-6.
29.
Ambroggio L, Tabb LP, O’Meara T, Sheffler-Collins S, McGowan KL, Shah SS. Influence of antibiotic susceptibility patterns on empiric antibiotic prescribing for children hospitalized with community-acquired pneumonia. Pediatr Infect Dis J 2012; 31: 331-6.
30.
Brogan TV, Hall M, Williams DJ, Neuman MI, Grijalva CG, Farris RWD, Shah SS. Variability in processes of care and outcomes among children hospitalized with community-acquired pneumonia. Pediatr Infect Dis J 2012; 31: 1036-41.
31.
Mandourah Y, Al-Radi A, Ocheltree AH, Ocheltree SR, Fowler RA. Clinical and temporal patterns of severe pneumonia causing illness during Hajj. BMC Infect Dis 2012; 12: 117.
32.
Ahmed QA, Arabi YM, Memish ZA. Health risks at the Hajj. Lancet 2006; 367: 1008-15.
33.
Gautret P, Soula G, Delmont J, Parola P, Brouqui P. Common health hazards in French pilgrims during the Hajj of 2007. A prospective cohort study. J Travel Med 2009; 16: 377-81.
34.
Alzahrani AG, Choudhry AJ, Al Mazroa MA, Turkistani AH, Nouman GS, Memish ZA. Pattern of diseases among visitors to Mina health centers during the Hajj season, 1429 H. J Infect Public Health 2012; 5: 22-34.
35.
Leekha S, Terrell CL, Edson RS. General principles of antimicrobial therapy. Mayo Clin Proc 2011; 86: 156-67.
36.
Anevlavis S, Bouros D. Community acquired bacterial pneumonia. Expert Opin Pharmacother 2010; 11: 361-74.
37.
Caliendo AM, Gilbert DN, Ginocchio CC, Hanson KE, May L, Quinn TC, Tenover FC, Alland D, Blaschke AJ, Bonomo RA, Carroll KC, Ferraro MJ, Hirschhorn LR, Joseph WP, Karchmern T, MacIntyre AT, Reller LB, Jackson AF; the Infectious Diseases Society of America (IDSA). Better Tests, Better Care: Improved Diagnostics for Infectious Diseases. Clin Infect Dis 2013; 57: S139-70.
38.
Niederman MS, Mandell LA, Anzueto A, Bass JB, Broughton WA, Campbell GD, Dean N, File T, Fine MJ,.
39.
Gross PA, Martinez F, Marrie TJ, Plouffe JF, Ramirez J, Sarosi GA, Torres A, Wilson R, Yu VL; American Thoracic Society. Guidelines for the management of adults with community-acquired pneumonia. Am J Respir Crit Care Med 2001; 163: 1730-54.
40.
Bartlett JG, Dowell SF, Mandell LA, File Jr TM, Musher DM, Fine MJ. Guidelines from the Infectious Diseases Society of America. Practice guidelines for the management of community-acquired pneumonia in adults. Clin Infect Dis 2000; 31: 347-82.
41.
Meehan TP, Fine MJ, Krumholz HM, Scinto JD, Galusha DH, Mockalis JT, Weber GF, Petrillo MK, Houck PM, Fine JM. Quality of care, process, and outcomes in elderly patients with pneumonia. JAMA 1997; 278: 2080-4.
42.
Nelson JM, Chiller TM, Powers JH, Angulo FJ. Fluoroquinolone-resistant Campylobacter species and the withdrawal of fluoroquinolones from use in poultry: a public health success story. Clin Infect Dis 2007; 44: 977-80.
43.
Croom KF, Goa KL. Levofloxacin: a review of its use in the treatment of bacterial infections in the United States. Drugs 2003; 63: 2769-802.
44.
Shah PB, Giudice JC, Griesback R Jr, Morley TF, Vasoya A. The newer guidelines for the management of community-acquired pneumonia. J Am Osteopath Assoc 2004; 104: 521-6.
45.
Gleason PP, Meehan TP, Fine JM, Galusha DH, Fine MJ. Association between antimicrobial therapy and medical outcomes for hospitalized elderly patients with pneumonia. Arch Intern Med 1999; 159: 2562-72.
46.
Stahl JE, Barza M, Desjardin J, Martin R, Eckman MH. Effect of macrolides as part of initial empiric therapy on length of stay in patients hospitalized with communityacquired pneumonia. Arch Intern Med 1999; 159: 2576-80.
47.
Macfarlane J, Holmes W, Gard P, Thornhill D, Macfarlane R, Hubbard R. Reducing antibiotic use for acute bronchitis in primary care: blinded, randomized controlled trial of patient information leaflet. BMJ 2002; 324: 91-4.
48.
Cassiere HA, Fein A. Duration and route of antibiotic therapy in community acquired pneumonia: switch and step down therapy. Semin Respir Infect 1998; 13: 36-42.
49.
Cunha BA. Meropenem in elderly and renally impaired patients. Int J Antimicrob Agents 1998; 10: 107-17.
50.
Saibal MAA, Rahman SHZ, Nishat L, Sikder NH, Begum SA, Islam MJ, Uddin KN. Community acquired pneumonia in diabetic and non-diabetic hospitalized patients: presentation, causative pathogens and outcome. Bangladesh Med Res Counc Bull 2012; 38: 98-103.
51.
Doi A, Iwata K, Takegawa H, Miki K, Sono Y, Nishioka H, Takeshita J, Tomii K, Haruta T. Community-acquired pneumonia caused by carbapenem-resistant Streptococcus pneumoniae: re-examining its prevention and treatment. Int J Gen Med 2014; 7: 253-7.
52.
Gupta N, Limbago BM, Patel JB, Kallen AJ. Carbapenemresistant Enterobacteriaceae: epidemiology and prevention. Clin Infec Dis 2011; 53: 60-7.
53.
Hong T, Moland ES, Abdalhamid B, Hanson ND, Wang J, Sloan C, Fabian D, Farajallah A, Levine J, Thomson KS. Escherichia coli: development of carbapenem resistance during therapy. Clin Infec Dis 2005; 40: e84-6.
54.
React Facts. Economic Aspects of Antibiotic Resistance. 2008. Available at: http://www.reactgroup.org/uplo... react-publications/economic-aspects-of-antibiotic-resistance.pdf [Accessed on 12-June-2015].
Share
RELATED ARTICLE
| eISSN: | 2300-6722 |
| ISSN: | 1899-1874 |
We process personal data collected when visiting the website. The function of obtaining information about users and their behavior is carried out by voluntarily entered information in forms and saving cookies in end devices. Data, including cookies, are used to provide services, improve the user experience and to analyze the traffic in accordance with the Privacy policy. Data are also collected and processed by Google Analytics tool (more).
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
